|
Back
to the articles...
| Procedure
Name Liver Biopsy Synonyms Blind Liver Biopsy; Needle
Biopsy of the Liver; Percutaneous Liver Biopsy
Applies to Percutaneous Needle Aspiration Biopsy Under
Fluoroscopic, CT, or Ultrasound Guidance; Transjugular Needle Biopsy of the Liver
Procedure Commonly Includes Percutaneous
biopsy of liver parenchyma in a "blind" fashion (ie, not under radiologic
guidance). This is carried out at the bedside under local anesthesia. A specialized,
thin-bore needle is advanced between the ribs overlying the region of hepatic dullness.
Several 2 cm cores of deep liver tissue are excised. Fresh specimens may be sent for gross
pathologic inspection, routine light microscopy, special stains for liver storage
diseases, transmission and immune electron microscopy, immunohistochemistry (using
monoclonal antibodies), DNA hybridization studies, and microbiologic culture. Liver biopsy
is a valuable and time-honored means of diagnosing diffuse liver parenchymal disease as
well as disseminated focal disease.
Indications Candidates for liver biopsy must be carefully
selected. This procedure, by nature, is invasive and histologic findings may often be
reported as "consistent with" a particular disease (without being pathognomonic)
or simply "nondiagnostic". In most cases, noninvasive imaging studies such as CT
scan or ultrasound are now obtained first. With these considerations in mind, indications
for liver biopsy include:
|
suspected cases of
liver cirrhosis, in order to confirm the diagnosis pathologically; establish etiology if
possible (alcohol, alpha1-antitrypsin deficiency, primary biliary cirrhosis,
Wilson's disease, hemochromatosis, etc); assess and stage level of activity; assess
complications |
|
chronic hepatitis,
with or without cirrhosis, to identify cases of chronic activity hepatitis (liver biopsy
mandatory for diagnosis) and differentiate this entity from chronic persistent hepatitis
and lobular hepatitis |
|
suspected liver
disease in the known alcoholic patient, to confirm alcoholic liver disease, exclude
alternative causes of liver disease (which may be present in 20% of cases), stage and assess disease activity |
|
diagnosis of hepatoma
or metastatic neoplasms |
|
suspected multisystem
disease with liver involvement, where traditional diagnostic techniques have not been
fruitful (eg, sarcoidosis, amyloidosis, tuberculosis, glycogen storage disease) |
|
staging of lymphoma |
|
unexplained
hepatomegaly |
|
cholestasis of
unknown etiology, where prior studies for biliary obstruction are negative |
|
persistently elevated
liver enzyme tests |
|
selected cases of
fever of unknown origin |
|
selected cases of
hepatitis of unknown etiology, in order to differentiate viral from drug-induced
etiologies (not always possible) or to assess complications, such as cholestasis |
|
evaluation of
response to treatment |
Liver biopsy is less useful in:
|
acute hepatitis A or
B infection, unless the diagnosis is in question |
|
extrahepatic biliary
obstruction, where percutaneous transhepatic cholangiography and ERCP are considered
first-line procedures |
|
fluid-filled liver
cysts detected on ultrasound or CT scan, probably more amenable to guided thin needle
aspiration first |
Contraindications Mahal et al (1979) noted that
failure to heed accepted contraindications led directly to 22 bleeding episodes in 3800
percutaneous liver biopsies.1 Contraindications include:
|
impaired hemostasis,
accepted as prothrombin time more than 3 seconds over control, PTT more than 20 seconds
over control, thrombocytopenia, and markedly prolonged bleeding time |
|
severe anemia (Hgb
<9.5 g/dL) |
|
local infection near
needle entry site, such as right sided pleural effusion or empyema, right lower lobe
pneumonia, local cellulitis, infected ascites or peritonitis |
|
tense ascites (low
yield technically, risk of leakage) |
|
high-grade
extrahepatic biliary obstruction with jaundice (increased risk of bile peritonitis) |
|
septic cholangitis |
|
possible hemangioma |
|
possible echinococcal
(hydatid) cyst |
|
lack of compatible
blood for transfusion |
|
uncooperative patient
|
Patient Preparation Procedures and risks of the
procedure are explained and consent is obtained. Formal consultation with gastroenterology
staff is usually required. Procedure entails overnight hospitalization in most cases but
some patients may be candidates for a "same day" outpatient biopsy. This latter
group is in good general health, not jaundiced, and displays no signs of liver failure
(ascites, encephalopathy). They need to stay within several minutes of the hospital for
1-2 days postbiopsy and must have supervision from family or friends. Scheduling
arrangements for both in-hospital and outpatient liver biopsies are handled by
gastroenterology team. All aspirin products and nonsteroidal agents must be discontinued
at least 5 days beforehand. If taking oral anticoagulants (Coumadin®), hospitalization is
required to convert to heparin therapy before biopsy. Patient is NPO after midnight the
evening prior. Daily medications may be taken on the day of procedure pending physician
approval. In some hospitals, patient drinks one to two glasses of milk in the early AM on
procedure day to empty the gallbladder. Screening laboratory studies ordered 24-48 hours
in advance commonly include CBC, PT/PTT, BUN, bleeding time, and type and crossmatch for
possible transfusion. Electrolytes and liver function tests are optional. If pneumonia or
pleural effusion suspected on examination, PA and lateral chest x-ray is obtained.
Premedication with meperidine and/or diazepam may be administered at physician discretion.
This is not routine in some centers due to possible toxicity.
Aftercare Protocols are individualized for each hospital.
In general, patient is monitored in a recovery area with frequent vital signs postbiopsy.
If no complications are apparent, patient is transferred back to hospital room by cart.
Strict bedrest is enforced for 24 hours; for the first 2 hours patient is positioned on
his right side. After 5 hours, patient may be allowed to sit up. Vitals (blood pressure,
pulse) are checked every 15-30 minutes for 2 hours, every 30 minutes for the next 2 hours,
and then every hour for 8 hours. Following this, vitals every 4 hours are permissible.
Physician should be immediately notified if hypotension, tachycardia, fever, or
uncontrolled pain occurs. Diet is restricted to clear liquids for several hours, then full
liquids as tolerated. Acetaminophen is usually sufficient for pain control. Some
physicians recheck hematocrit 24 hours after procedure before approving hospital
discharge.
Special Instructions In the appropriate
high-risk patient, antibiotic prophylaxis for infective endocarditis may be considered.
Little data exists regarding the risk of bacteremia, however, much less endocarditis.
Complications Based on several large series, serious
morbidity has been estimated at 0.1% to 0.2%. Fatality rates have ranged from 0% to 0.17%,
both figures being derived from studies involving >20,000 biopsies each. The more
commonly seen complications are:
|
pain - the most
common adverse event, noted in 50% of
cases. Usually it is confined to the right shoulder, probably referred pain from
diaphragmatic pleura. Analgesia is required in approximately 20% of patients with
acetaminophen sufficient in most cases. Symptoms resolve in 1-2 days. |
|
hemorrhage - minor
episodes are common. Self-limited oozing from the puncture site may persist for
approximately 1 minute, but with loss of only 5-10 mL blood. Significant hemorrhage is
less frequent but is the most common cause of death from liver biopsy. Several series have
estimated an incidence of approximately 0.2%, but Sherlock (1984) reported 40 patients out
of 6379 required transfusion for intraperitoneal bleeding.2 She felt these
statistics may even underestimate the incidence since those with severe coagulopathies
were excluded. Bleeding usually results from a tear of a distended portal or hepatic vein.
Specific sites include the abdominal cavity (hemoperitoneum), liver capsule (capsular
hematoma), liver parenchyma (intrahepatic hematoma), or biliary tree (hemobilia).
Postulated risk factors are coagulopathy, amyloid liver, hepatocellular injury,
hemangioma, and vascularized tumor. However, bleeding may be massive when no risk factors
are present. Not all episodes require surgery. In a study 4 of 7532 patients needed
surgical intervention while 12 others with severe hemorrhage were transfused and observed.
|
|
bile leakage with
peritonitis - associated with severe obstruction of the larger bile ducts. This is felt to
result from laceration of a small, distended duct or from puncture of the gallbladder.
With the widespread use of noninvasive imaging, the size of the bile ducts is known
prebiopsy and the complication rate has declined. |
|
laceration of
internal organs and viscera - right kidney, gallbladder, colon, pancreas, and others |
|
others: right-sided
pneumothorax, arteriovenous fistula - 5.4% of all biopsies, drug toxicity |
Equipment Several biopsy needles are available.
|
Menghini needle - 1.9
mm diameter steel shaft with sharpened beveled tip and syringe; specimen is obtained using
suction/aspiration into a 10 mL syringe. Requires only 1 second within the liver
("1-second technique") and patient need not hold his breath. Disadvantages are
small samples and fragmentation of biopsy specimens. |
|
"Trucut"
needle - disposable 2.05 mm diameter needle designed to cut out cores of tissue. Specimens
are less fragmented, even in the cirrhotic liver, and thus a high success rate. However,
dwell time in liver is longer (5-10 seconds), patient must cooperate more, and several
steps are necessary. |
|
Vim-Silverman needle
- sheath with inner cutting blade (similar to a "punch" biopsy). Trucut needle
is a modernized Vim-Silverman. |
Technique Patient lies supine in bed with right hand behind
his head. Liver margins are estimated by percussion. Two approaches are popular,
transthoracic (intercostal) or subcostal (anterior). With the former, biopsy site is
identified along the midaxillary line in the center of hepatic dullness, usually the
eighth or ninth intercostal space. This approach avoids other abdominal organs but always
penetrates the pleura. With the subcostal approach, the biopsy site lies below the bottom
rib anteriorly, and is used when a liver mass is easily palpable below the right costal
margin. The risk of visceral laceration is higher and this approach is infrequently used;
fine needle aspiration under CT guidance has become more popular. A wide area is prepped
and draped in sterile fashion with operators in gowns, gloves, and masks. The skin is
anesthetized with 1% lidocaine, then deeper structures are infiltrated - subcutaneous
tissue, intercostal muscles, and diaphragm. Some operators make a small superficial
incision with a No 11 blade at the needle entry site to facilitate needle insertion.
Techniques differ with the type of biopsy needle selected. In general, the biopsy needle
is advanced as far as the diaphragm (depth estimated by a finder needle). If a Menghini
needle is used, suction is applied to the syringe, the needle is pushed rapidly through
the pleura and into the liver parenchyma. A 2.5 cm core of liver is aspirated and needle
withdrawn, all within 1 second. If other needles are used, patient may need to hold his
breath at end expiration to decrease the risk of pneumothorax. Several passes of the
biopsy needle are performed to minimize sampling bias.
Specimen At least two to three liver cores, each >2 cm in
length. Initial specimen processing and transportation handled by gastroenterology team. A
typical protocol would be as follows:
|
tissue fixation - for
light microscopy, specimen is routinely fixed in 10% buffered formalin within 1 minute.
For transmission electron microscopy, 1 mm cubes of specimen are fixed immediately in
glutaraldehyde with further processing in Pathology Laboratory. |
|
routine tissue stains
including: H & E - general liver histology stain; reticulin stain - for connective
tissue, especially cirrhosis, fibrosis, bridging necrosis; trichrome - fibrosis; iron
stain - useful for hemosiderosis, hemochromatosis, bile pigments; diastase PAS stain -
useful for alpha1-antitrypsin globules, bile ducts, iron; orcein - for
hepatitis B surface antigen (if present, fine granular brown material stains in
hepatocytes). Also for copper-binding protein in Wilson's disease. |
|
cytologic preparation
- fluid from aspirating syringe may be smeared on clean microscope slide, fixed, and sent
to Cytology Laboratory |
|
microbiological
culture - specimen sent without fixative in sterile container. Special stains (AFB, KOH,
etc) and cultures (tuberculosis, viral, Brucella, parasites, fungi) as needed |
|
optional special
stains (ie, congo red for amyloidosis, immunohistochemistry) |
Footnotes
|
1. Mahal AS, Knauer CM, and Gregory PB, "Bleeding After Liver
Biopsy,"West J Med, 1981, 134(1):11-4. |
|
2. Sherlock S, Dick R, and van Leeuwen DJ, "Liver Biopsy Today. The
Royal Free Hospital Experience,"J Hepatol, 1984, 1(1):75-85. |
References
|
Lefkowitch JH, "Pathologic Diagnosis of Liver Disease,"Hepatology:
A Textbook of Liver Disease, 2nd ed, Chapter 29, Zakim D and Boyer TD, eds,
Philadelphia, PA: WB Saunders Co, 1990, 711-32. |
|
Perrault J, McGill DB, Ott BJ, et al, "Liver Biopsy: Complications in
1000 Inpatients and Outpatients,"Gastroenterology, 1978, 78(1):103-6. |
|
Schaffner F, "Needle Biopsy of the Liver,"Bockus
Gastroenterology, 4th ed, Chapter 49, Berk JE, ed, Philadelphia, PA: WB Saunders Co,
1985, 657-66. |
|
Sherlock S, "Needle Biopsy of the Liver,"Diseases of the
Liver and Biliary System, 7th ed, Chapter 3, Oxford, England: Blackwell Scientific
Publications, 1985, 28-37. |
|
Van Ness MM and Diehl AM, "Is Liver Biopsy Useful in the Evaluation
of Patients With Chronically Elevated Liver Enzymes?"Ann Intern Med, 1989,
111(6):473-8. Back to the
articles... |
|
|